Steven D. Gore, MD – Medical Officer, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Inst
20 years of ‘Epigenetic’ Cancer Therapy - Who are We Fooling?
Tuesday, September 22, 2020 | 8:00 AM
Until very recently, Dr. Gore served as the Director of Hematologic Malignancies at the Yale Cancer Ctr, which he joined as Professor of Medicine (Hematology) in 2013. Prior to Yale, he spent 23 years on the faculty of the Sidney Kimmel Comprehensive Cancer Ctr at Johns Hopkins in the Division of Hematologic Malignancies. Dr. Gore has been recognized as a leader in clinical and translational research in myeloid malignancies, especially myelodysplastic syndrome and clinical applications of epigenetics in cancer therapeutics. He was co-chair of the Leukemia Steering Committee for the National Clinical Trials Network and a member of the Leukemia Core Committee and Leukemia Laboratory Committee of the Eastern Cooperative Oncology Group. Dr. Gore has developed several National Cancer Inst and pharma-sponsored early-phase trials with translational endpoints, as well as multicenter and cooperative group protocols in myelodysplastic syndrome, including the first randomized trial comparing the impact of the addition of a histone deacetylase inhibitor to a DNA methyltransferase inhibitor in myelodysplastic syndrome. He has chaired eight biannual international workshops on the Clinical Translation of Epigenetic Therapy in Cancer Therapeutics. He has served on a variety of Cancer Ctr and pharmaceutical advisory boards. In his new position, Dr. Gore holds a portfolio of drugs in the DNA Damage and Repair space, helping to develop and monitor NCI-sponsored clinical trials in cancer. See Dr. Gore's CV.